Author + information
Bioresorbable vascular scaffolds was shown to be safe in chronic stable coronary artery disease. However, the role of bioresorbable vascular scaffolds (BRS) in acute coronary syndrome (ACS) patients remains unclear. The aim of the study is to study long-term result of the application of bioresorbable vascular scaffolds in acute coronary syndrome.
Consecutive ACS patients receiving BRS implantation were collected in a tertiary medical center. Major adverse cardiac event (MACE), myocardial infarction, and target lesion revascularization (TLR) were the primary endpoint.
After a median follow-up of 14.5 months, there were total 50 patients, including ST elevation myocardial infarction (n=10), non-ST elevation myocardial infarction (n=13) and unstable angina (n=27). The ratio of the male was 90%. The proportion of diabetes mellitus was 26%. The number of the vessel include single vessel disease (36%), double vessel disease (28%) and triple vessel disease (32%). The number of BRS implantation were different among STEMI, NSTEMI and unstable angina, All STEMI patients only received one stent. However, more stents were implanted in unstable or NSTEMI patients, including: 1 stent (55.6%), 2 stents (33.3%), 3 stents (3.7%) and 4 stents (7.4%). The size of stent implantation included 2.5 mm (18.8%), 3.0 mm(39.6%) and 3.5 mm (37.5%).The length of stent implantation included 18 mm (12.2%), 23 mm (18.4%) and 28 mm(61.2%). There was no any major adverse cardiac event (MACE), myocardial infarction, and target lesion revascularization identified.
This study demonstrated bioresorbable vascular scaffolds was safe and feasible in patients after acute coronary syndrome in one-year follow-up in Taiwan.